Chinese healthcare outpatient clinic group Meinian Onehealth Healthcare has increased its offer to rival iKang, which aims to delist from NASDAQ, to US$23.50 per American Depositary Share (ADS). This comes two weeks after iKang adopted a poison pill in response to Meinian's original counter-bid to take the group private, giving the right to its shareholders to buy more shares if Meinian manages to acquire a stake.